Rolls-Royce Motor Cars chose to mark the debut of the all-new Ghost sedan in Asia-Pacific via South Korea due to the country's importance to the carmaker's business.
Paul Harris, Asia-Pacific regional director of Rolls-Royce, noted it is no coincidence that the Asia-Pacific debut was in South Korea as it is a trendsetter in fashion, art, and architecture.
The car was globally unveiled on Tuesday.
The New Ghost sells at the starting price of 471 million won with delivery scheduled to begin in December.
Rolls-Royce was seeking to capture the growing demand for high-end models.
According to the Korea Automobile Importers and Distributors Association (KAIDA), Rolls-Royce's vehicle sales in South Korea expanded 31 percent to 161 units in 2019 from 123 a year earlier.
The Goodwood-based carmaker began selling vehicles in South Korea 16 years ago. Other cars in its lineup are the Phantom, Dawn, Wraith, and Cullinan.
Rolls-Royce belongs to the BMW Group, which sold 43,818 vehicles is SAouth Korea in 2019, up 35 percent from 32,531 units the previous year.


SK Hynix Shares Surge on Record $28.6 Billion Buyback
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
REPAY Stock Rises After Visa Platform Connect Collaboration
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Google to Move All Pixel Production Out of China by 2027
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits
Coty Revenue Beats Estimates as Beauty Demand Holds Firm
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 



